Lumos Pharma, Inc.
LUMO
$-0.02
Change (1 day)
$4.58
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Revenue of Lumos Pharma, Inc. (LUMO)
Revenue in 2023 (TTM): $2.05 M
According to Lumos Pharma, Inc.'s latest financial reports the company's current revenue (TTM) is $2.05 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lumos Pharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.05 M | $2.01 M | $-36,570,000 | $-34,063,000 | $-34,034,000 |
| 2022 | $1.52 M | $1.47 M | $-31,991,000 | $-31,075,000 | $-31,062,000 |
| 2021 | $230 K | $230 K | $-31,130,000 | $-31,066,000 | $-30,430,000 |
| 2020 | $168 K | $168 K | $-25,719,000 | $-19,636,000 | $-5,663,000 |
| 2019 | $936 K | $899 K | $-45,134,000 | $-42,977,000 | $-42,989,000 |
| 2018 | $1.21 M | $12.47 M | $-59,366,000 | $-60,563,000 | $-53,595,000 |
| 2017 | $390 K | $-1,017,000 | $-70,984,000 | $-72,510,000 | $-71,951,000 |
| 2016 | $3.53 M | $3.53 M | $-88,405,000 | $-90,511,000 | $-85,155,000 |
| 2015 | $36.14 M | $68.5 M | $-31,946,000 | $-33,643,000 | $-40,381,000 |
| 2014 | $165.95 M | $172.59 M | $118.76 M | $117.63 M | $102.86 M |
| 2013 | $1.09 M | $1.09 M | $-30,126,000 | $-31,050,000 | $-31,180,000 |
| 2012 | $1.69 M | $1.69 M | $-22,495,000 | $-23,321,000 | $-23,321,000 |
| 2011 | $1.87 M | $1.87 M | $-17,519,000 | $-18,088,000 | $-18,087,000 |
| 2010 | $2.08 M | $2.08 M | $-16,077,000 | $-16,590,000 | $-16,213,000 |
| 2009 | $934 K | $934 K | $-9,895,000 | $-9,798,000 | $-9,442,000 |
| 2008 | $633 K | $633 K | $-9,121,000 | $-9,373,000 | $-9,162,000 |